NurExone Appoints Eyal Gabbai to Board, Adding Large-Scale Healthcare System and Capital Markets Expertise

Core Viewpoint - NurExone Biologic Inc. has appointed Mr. Eyal Gabbai to its Board of Directors, replacing Dr. Gadi Riesenfeld, who will continue to support the company as a member of the Scientific Advisory Board [1][4]. Company Developments - Mr. Gabbai's experience in healthcare leadership and capital markets is expected to be valuable as NurExone advances its preclinical programs and evaluates future capital market opportunities [2]. - The appointment reflects the company's focus on engaging with partners who understand patient needs and healthcare economics, with Mr. Gabbai bringing extensive experience in healthcare systems and public company environments [3]. Leadership Background - Mr. Gabbai is currently the Chairman of Meuhedet Health Fund, which has approximately 1.4 million members and an annual turnover exceeding US$3 billion [3]. - He has previously held significant positions, including Director-General of Israel's Prime Minister's Office and Director General of Israel's Government Companies Authority, leading major transactions exceeding US$5 billion [3]. Company Focus and Products - NurExone is focused on developing regenerative exosome-based therapies for central nervous system injuries, with its lead product, ExoPTEN, showing strong preclinical data for treating acute spinal cord and optic nerve injuries, both of which are multi-billion-dollar markets [5]. - The company has received Orphan Drug Designation, facilitating its roadmap towards clinical trials in the U.S. and Europe [5]. - NurExone aims to provide solutions for companies interested in quality exosomes and minimally invasive targeted delivery systems [5].